​

Fate Therapeutics Ownership | Who Owns Fate Therapeutics?

OverviewForecastRevenueFinancialsChart

Fate Therapeutics Ownership Summary

Fate Therapeutics is owned by 67.07% institutional investors, 1.71% insiders, and 31.22% retail investors. Redmile group is the largest institutional shareholder, holding 10.86% of FATE shares. BB Biotech AG Ord is the top mutual fund, with 4.25% of its assets in Fate Therapeutics shares.

FATE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockFate Therapeutics67.07%1.71%31.22%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Redmile group12.87M10.86%$14.42M
Blackrock10.12M10.01%$33.18M
Blackrock funding, inc. /de10.81M9.12%$12.11M
Vanguard group10.33M8.77%$17.05M
Boxer capital8.22M8.13%$26.95M
Morgan stanley3.15M3.11%$10.33M
Johnson & johnson3.38M2.85%$3.51M
Dimensional fund advisors lp2.90M2.46%$4.78M
Vestal point capital, lp2.52M2.12%$2.82M
Goldman sachs group2.48M2.10%$4.09M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Redmile group12.87M1.53%$14.42M
Boxer capital8.22M1.42%$26.95M
Johnson & johnson3.38M1.05%$3.51M
Bruce429.19K0.16%$480.69K
Vestal point capital, lp2.52M0.15%$2.82M
Monaco asset management sam675.00K0.13%$756.00K
Tang capital management1.87M0.11%$2.09M
Artal group1.03M0.09%$3.39M
Parametrica management18.47K0.04%$20.69K
Privium fund management b.v.87.00K0.03%$143.55K

Top Buyers

HolderShares% AssetsChange
Blackrock10.12M0.00%1.02M
Citigroup781.89K0.00%707.68K
Ubs group1.10M0.00%699.11K
Artal group1.03M0.09%672.19K
Dimensional fund advisors lp2.90M0.00%279.36K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---5.57M
Bellevue group---4.84M
Deerfield management company, l.p. (series c)---3.56M
Ecor1 capital---3.05M
State street2.23M0.00%-3.03M

New Positions

HolderShares% AssetsChangeValue
Headlands49.56K0.01%49.56K$55.50K
China universal asset management24.15K0.00%24.15K$39.85K
Quinn opportunity partners20.00K0.00%20.00K$22.40K
Narwhal capital management12.70K0.00%12.70K$14.22K
Hbk sorce advisory12.13K0.00%12.13K$13.59K

Sold Out

HolderChange
Mather group, llc.-5.00
Innealta capital-9.00
Chris bulman-10.00
Nelson, van denburg & campbell wealth management group-17.00
Evermay wealth management-25.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20251384.55%79,496,955-17.58%671.01%7022.81%40-2.44%
Mar 31, 20256-96.23%21,342,655-78.99%180.25%2-97.40%1-97.92%
Dec 31, 2024157-3.68%101,473,772-11.49%860.91%7620.63%47-16.07%
Sep 30, 2024163-9.94%114,640,778-6.17%970.67%63-33.68%5718.75%
Jun 30, 20241817.74%122,176,866-0.69%1200.82%956.74%48-5.88%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord4.84M4.25%-
Vanguard US Total Market Shares ETF3.05M2.66%-
Vanguard Total Stock Mkt Idx Inv2.98M2.60%-65.80K
Vanguard Strategic Equity Inv2.54M2.22%-
iShares Russell 2000 ETF2.54M2.22%-48.30K
SPDR® S&P Biotech ETF2.34M2.06%33.31K
Vanguard Explorer Inv1.27M1.11%-
Fidelity Small Cap Index1.03M0.90%-7.96K
Vanguard Institutional Extnd Mkt Idx Tr964.45K0.84%-439.47K
BlackRock Advantage Small Cap Core Instl945.76K0.82%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 04, 2025TAHL CINDY See RemarksSell$9.57K
Aug 04, 2025Valamehr Bahram President and CEOSell$15.40K
Jan 10, 2025Bressi Jerome Charles See RemarksSell$9.27K
Jan 10, 2025TAHL CINDY See RemarksSell$8.76K
Jan 10, 2025Valamehr Bahram President and CEOSell$13.41K

Insider Transactions Trends

DateBuySell
2025 Q3-2
2025 Q2--
2025 Q1-3
2024 Q411
2024 Q3-1

FATE Ownership FAQ

Who Owns Fate Therapeutics?

Fate Therapeutics shareholders are primarily institutional investors at 67.07%, followed by 1.71% insiders and 31.22% retail investors. The average institutional ownership in Fate Therapeutics's industry, Biotech Stocks , is 306.59%, which Fate Therapeutics falls below.

Who owns the most shares of Fate Therapeutics?

Fate Therapeutics’s largest shareholders are Redmile group (12.87M shares, 10.86%), Blackrock (10.12M shares, 10.01%), and Blackrock funding, inc. /de (10.81M shares, 9.12%). Together, they hold 29.99% of Fate Therapeutics’s total shares outstanding.

Does Blackrock own Fate Therapeutics?

Yes, BlackRock owns 10.01% of Fate Therapeutics, totaling 10.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 33.18M$. In the last quarter, BlackRock increased its holdings by 1.02M shares, a 11.17% change.

Who is Fate Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Fate Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.53% of its assets in 12.87M Fate Therapeutics shares, valued at 14.42M$.

Who is the top mutual fund holder of Fate Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Fate Therapeutics shares, with 4.25% of its total shares outstanding invested in 4.84M Fate Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools